Pickett W C, Austen K F, Goetzl E J
J Cyclic Nucleotide Res. 1979;5(3):197-209.
Ascorbate induces a 10- to 25-fold rise in platelet guanosine 3'5'-cyclic monophosphate (cGMP) and this action is prevented or reversed by the introduction of aspirin, indomethacin, ro 5,8,11,14-eicosatetraenoic acid (TYA). The reversal was 70-90% complete at 30 s, the earliest time point that was examined. As the effect of ascorbate on cGMP was not diminished by anaerobic conditions, which inhibited the oxidation of exogenous arachidonate by more than 95%, metabolic inhibition of cyclo-oxygenase activity did not duplicate the effect of the non-steroidal anti-inflammatory agents. Ascorbate did not act by the activation of phospholipase A2 in that the ascorbate-induced evevation of cGMP was not accompanied by increased oxygen consumption or the release of [14C]-arachidonate from prelabeled platelets. Thus, despite the finding that non-steroidal anti-inflammatory agents prevent and reverse the ascorbate-mediated elevation of cGMP, it was not possible to relate their respective antagonist and agonist actions to the oxidation of arachidonate.
抗坏血酸可使血小板鸟苷 3',5'-环磷酸(cGMP)升高 10 至 25 倍,而阿司匹林、吲哚美辛、罗 5,8,11,14-二十碳四烯酸(TYA)可阻止或逆转这一作用。在最早检测的 30 秒时,逆转程度达 70%至 90%。由于厌氧条件(可使外源性花生四烯酸的氧化抑制超过 95%)并未减弱抗坏血酸对 cGMP 的作用,因此环氧化酶活性的代谢抑制并不能复制非甾体抗炎药的作用。抗坏血酸并非通过激活磷脂酶 A2 起作用,因为抗坏血酸诱导的 cGMP 升高并未伴随耗氧量增加或从预先标记的血小板中释放出[14C]-花生四烯酸。因此,尽管发现非甾体抗炎药可预防和逆转抗坏血酸介导的 cGMP 升高,但无法将它们各自的拮抗和激动作用与花生四烯酸的氧化联系起来。